0001493152-26-014131
SEC filingOperating and net losses deepened to -$11.9M and -$11.7M respectively in FY2025, driven by elevated investor relations advertising costs that outpaced R&D savings from leadership retirement, amid a strategic pivot and ongoing cash burn.
Cash flow pressures persisted, with net cash provided by operating activities at -$9.5 million versus -$7.3 million prior year. Management notes the Company has historically experienced negative operating cash flows from research and development investments, and does not expect positive cash flows in the near future. This reflects a January 2025 change order with CRO Theradex Systems, Inc. to support Ropidoxuridine clinical trials, even as the Company anticipates ceasing future R&D activities until defining its preclinical and clinical drug development direction.
Liquidity is managed on a going concern basis, contemplating normal realization of assets and satisfaction of liabilities. Legal and professional fees decreased due to lower public filing, contract, and financing-related work compared to FY2024. To navigate this pivot, management engaged Bowery Consulting for advice on scaling activities, growth and capital raising strategies, and cost minimization tied to technological platform improvements and marketing spend. This positions SHPH to evaluate AI-driven drug discovery opportunities while addressing operational burn in a capital-constrained environment.